Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The potential for prostate cancer immunotherapy.

Brian I Rini1, Eric J Small

  • 1University of California San Francisco (UCSF) Comprehensive Cancer Center, USA. brini@medicine.ucsf.edu

Critical Reviews in Oncology/Hematology
|July 10, 2003
PubMed
Summary

Understanding the immune system

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.

Nature·2026
Same author

Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment Landscape.

Oncology and therapy·2026
Same author

Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma.

European urology·2026
Same author

Cardiac biomarkers in patients with renal cell carcinoma treated with immune checkpoint inhibitors.

The oncologist·2026
Same author

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.

Journal for immunotherapy of cancer·2026
Same author

Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization.

Nature reviews. Clinical oncology·2026

Area of Science:

  • Immunology
  • Oncology
  • Cancer Immunotherapy

Background:

  • Effective immune responses are well-understood.
  • Immune dysfunction in cancer presents therapeutic opportunities.
  • Immunotherapy aims to modulate the immune system against cancer.

Purpose of the Study:

  • To review current immunotherapeutic strategies for cancer.
  • To highlight approaches targeting dendritic cell (DC) functions.
  • To assess the clinical success of these therapies, particularly in prostate cancer.

Main Methods:

  • Review of recent advancements in cancer immunology.
  • Analysis of immunotherapeutic strategies including DC stimulation, antigen presentation, and antibody therapy.
  • Evaluation of clinical outcomes in prostate cancer treatment.

Main Results:

  • Various immunotherapeutic approaches have been developed.
  • Strategies successfully stimulate desired immune responses in preclinical models.
  • Limited clinical success has been observed to date.

Conclusions:

  • Immunotherapy holds promise for cancer treatment.
  • Further research is needed to improve clinical efficacy.
  • Targeting immune components offers a viable therapeutic avenue.

Related Experiment Videos